FORT COLLINS, Colo. & MADISON, Wisc.--(BUSINESS WIRE)--Inviragen has received a Small Business Technology Transfer award from the National Institutes of Health to support its collaboration with the University of Wisconsin to develop a safe and effective avian influenza vaccine. The two-year, $600,000 grant will fund the construction and testing of novel vaccines designed to protect against the highly pathogenic H5N1 avian influenza virus. “We are pleased to receive funding from the NIH for support of our avian influenza vaccine research efforts,” said Dr. Dan Stinchcomb, Inviragen’s Chief Executive Officer. “This new project combines Inviragen’s expertise in genetic engineering of vaccines for respiratory diseases with the world-renowned influenza expertise at University of Wisconsin.”
